Ad is loading...
OFALX
Price
$20.84
Change
-$0.06 (-0.29%)
Updated
Nov 15 closing price
VIVAX
Price
$68.72
Change
-$0.26 (-0.38%)
Updated
Nov 15 closing price
Ad is loading...

OFALX vs VIVAX

Header iconOFALX vs VIVAX Comparison
Open Charts OFALX vs VIVAXBanner chart's image
Olstein All Cap Value C
Price$20.84
Change-$0.06 (-0.29%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index I
Price$68.72
Change-$0.26 (-0.38%)
VolumeN/A
CapitalizationN/A
OFALX vs VIVAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
OFALX vs. VIVAX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OFALX is a Buy and VIVAX is a StrongSell.

FUNDAMENTALS
Fundamentals
VIVAX has more cash in the bank: 184B vs. OFALX (569M). VIVAX pays higher dividends than OFALX: VIVAX (2.25) vs OFALX (0.12). OFALX was incepted earlier than VIVAX: OFALX (29 years) vs VIVAX (32 years). OFALX is a more actively managed with annual turnover of: 32.00 vs. VIVAX (10.00). OFALX has a lower initial minimum investment than VIVAX: OFALX (1000) vs VIVAX (3000). VIVAX annual gain was more profitable for investors over the last year : 25.55 vs. OFALX (23.84). VIVAX return over 5 years is better than : 50.81 vs. OFALX (5.27).
OFALXVIVAXOFALX / VIVAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence29 years32 years-
Gain YTD13.19917.91274%
Front LoadN/AN/A-
Min. Initial Investment1000300033%
Min. Initial Investment IRAN/AN/A-
Net Assets569M184B0%
Annual Yield % from dividends0.122.255%
Returns for 1 year23.8425.5593%
Returns for 3 years-23.6721.58-110%
Returns for 5 years5.2750.8110%
Returns for 10 years-1.80110.46-2%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LI22.720.49
+2.20%
Li Auto
ICCC3.610.01
+0.28%
ImmuCell Corp
BXC120.39-0.95
-0.78%
BlueLinx Holdings
LNTH76.83-4.01
-4.96%
Lantheus Holdings
PSTX2.76-0.45
-14.02%
Poseida Therapeutics